Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cardiotoxicity of HER2-targeted therapies
Robert S. Copeland-Halperin, Jennifer E. Liu, Anthony F. Yu
Current Opinion in Cardiology (2019) Vol. 34, Iss. 4, pp. 451-458
Open Access | Times Cited: 71

Showing 1-25 of 71 citing articles:

Targeted therapy for breast cancer: An overview of drug classes and outcomes
Aaron T. Jacobs, Diana Martinez Castaneda-Cruz, Mark M. Rose, et al.
Biochemical Pharmacology (2022) Vol. 204, pp. 115209-115209
Open Access | Times Cited: 85
Locally misfolded HER2 expressed on cancer cells is a promising target for development of cancer-specific antibodies
Takao Arimori, Emiko Mihara, Hiroyuki Suzuki, et al.
Structure (2024) Vol. 32, Iss. 5, pp. 536-549.e5
Closed Access | Times Cited: 14
A Cancer-Specific Monoclonal Antibody against HER2 Exerts Antitumor Activities in Human Breast Cancer Xenograft Models
Mika K. Kaneko, Hiroyuki Suzuki, Tomokazu Ohishi, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 3, pp. 1941-1941
Open Access | Times Cited: 12
Establishment of a Novel Cancer-Specific Anti-HER2 Monoclonal Antibody H2Mab-250/H2CasMab-2 for Breast Cancers
Mika K. Kaneko, Hiroyuki Suzuki, Yukinari Kato
Monoclonal Antibodies in Immunodiagnosis and Immunotherapy (2024) Vol. 43, Iss. 2, pp. 35-43
Open Access | Times Cited: 11
Structural Basis for Inhibition of Mutant EGFR with Lazertinib (YH25448)
David E. Heppner, Florian Wittlinger, Tyler S. Beyett, et al.
ACS Medicinal Chemistry Letters (2022) Vol. 13, Iss. 12, pp. 1856-1863
Open Access | Times Cited: 31
Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer
Giuseppe Curigliano, Rebecca Dent, H. Earle, et al.
ESMO Open (2024) Vol. 9, Iss. 4, pp. 102989-102989
Open Access | Times Cited: 6
Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines
Christine Simmons, Daniel Rayson, Anil A. Joy, et al.
Therapeutic Advances in Medical Oncology (2022) Vol. 14
Open Access | Times Cited: 23
Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel
Joanne Chiu, Soo Chin Lee, Jcm Ho, et al.
Drug Safety (2023) Vol. 46, Iss. 10, pp. 927-949
Open Access | Times Cited: 13
Nanotechnology Applications in Breast Cancer Immunotherapy
Ruijie Wang, Pramod Kumar, Moataz Reda, et al.
Small (2023)
Closed Access | Times Cited: 13
Breast Cancer Treatment Strategies Targeting the Tumor Microenvironment: How to Convert “Cold” Tumors to “Hot” Tumors
Liucui Yang, Qingyi Hu, Tao Huang
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 13, pp. 7208-7208
Open Access | Times Cited: 4
Association Between Advanced TNM Stages and Increased Risk of Cardiac Dysfunction in Patients with LVEF < 50%
Sergiu Ioan Murg, Loredana Matiș, Andrada Florina Moldovan, et al.
Medicina (2025) Vol. 61, Iss. 2, pp. 301-301
Open Access
SGLT2 inhibitors for prevention and management of cancer treatment-related cardiovascular toxicity: a review of potential mechanisms and clinical insights
Carl Simela, John M. Walker, Arjun K. Ghosh, et al.
Cardio-Oncology (2025) Vol. 11, Iss. 1
Open Access
The mechanism and treatment of targeted anti-tumour drugs induced cardiotoxicity
Xiao Zhang, Yiqiang Gao, Benyu Yang, et al.
International Immunopharmacology (2023) Vol. 117, pp. 109895-109895
Closed Access | Times Cited: 10
Locally Misfolded HER2 Expressed on Cancer Cells is a Promising Target for Development of Cancer-Specific Antibodies
Takao Arimori, Emiko Mihara, Hiroyuki Suzuki, et al.
(2023)
Closed Access | Times Cited: 9
Anti-HER2 cancer-specific mAb, H2Mab-250-hG<sub>1</sub> possesses higher complement-dependent cytotoxicity than trastuzumab
Hiroyuki Suzuki, Tomokazu Ohishi, Tomohiro Tanaka, et al.
(2024)
Open Access | Times Cited: 3
Anti-HER2 Cancer-Specific mAb, H2Mab-250-hG1, Possesses Higher Complement-Dependent Cytotoxicity than Trastuzumab
Hiroyuki Suzuki, Tomokazu Ohishi, Tomohiro Tanaka, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 15, pp. 8386-8386
Open Access | Times Cited: 3
Cardio-Oncology and Heart Failure: A Scientific Statement from the Heart Failure Society of America
Michelle Bloom, Jacqueline B. Vo, Jo E. Rodgers, et al.
Journal of Cardiac Failure (2024)
Closed Access | Times Cited: 3
Quality of Life and Symptom Management in Advanced Biliary Tract Cancers
Lindsay Hunter, Heloisa P. Soares
Cancers (2021) Vol. 13, Iss. 20, pp. 5074-5074
Open Access | Times Cited: 23
A Cancer-Specific Monoclonal Antibody against Podocalyxin Exerted Antitumor Activities in Pancreatic Cancer Xenografts
Hiroyuki Suzuki, Tomokazu Ohishi, Tomohiro Tanaka, et al.
International Journal of Molecular Sciences (2023) Vol. 25, Iss. 1, pp. 161-161
Open Access | Times Cited: 8
The role of cardiac magnetic resonance imaging in the detection and monitoring of cardiotoxicity in patients with breast cancer after treatment: a comprehensive review
Fatemeh Jafari, Afsane Maddah Safaei, Leila Hosseini, et al.
Heart Failure Reviews (2020) Vol. 26, Iss. 3, pp. 679-697
Closed Access | Times Cited: 21
Identification of ADME genes polymorphic variants linked to trastuzumab-induced cardiotoxicity in breast cancer patients: Case series of mono-institutional experience
Nicoletta Staropoli, Francesca Scionti, Valentina Farenza, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 174, pp. 116478-116478
Open Access | Times Cited: 2
Cardiorenal Impact of Anti-Cancer Agents: The Intersection of Onco-Nephrology and Cardio-Oncology
Rose Mary Attieh, Belen Nunez, Robert S Copeland-Halperin, et al.
Cardiorenal Medicine (2024), pp. 1-1
Open Access | Times Cited: 2
Approaches to Improve the Translation of Safety, Pharmacokinetics and Therapeutic Index of ADCs
Qihong Huang, Minu Pilvankar, Rakesh Dixit, et al.
Xenobiotica (2024) Vol. 54, Iss. 8, pp. 533-542
Closed Access | Times Cited: 2
Molecular biomarkers of progression in non-muscle-invasive bladder cancer — beyond conventional risk stratification
Mitchell Olislagers, Florus C. de Jong, Vera C Rutten, et al.
Nature Reviews Urology (2024)
Closed Access | Times Cited: 2
UACA locus is associated with breast cancer chemoresistance and survival
Qianqian Zhu, Emily Schultz, Jirong Long, et al.
npj Breast Cancer (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top